IPO Profile: Inotek Pharmaceuticals Corp

Company Details

Lexington, Mass.



Description: Inotek Pharmaceuticals Corporation is a United States-based company, which is engaged in developing molecules with mechanisms of action to fulfill medical needs in diseases of the eye. The company’s lead program, trabodenoson (INO-8875), is a highly selective adenosine mimetic, which selectively agonizes the adenosine A1 receptor. The company’s portfolios of poly (ADP-ribose) polymerase (PARP) inhibitors are in the preclinical development phase for diabetic retinopathy and age-related macular degeneration.

IPO Details

Exchange and Ticker: Nasdaq: ITEK

Filing Range: 6.67 million shares @ $6.00 to $6.00

Date of IPO: 2/18/15

Offering Price: $6.00

Offering Size: $40M

Shares Outstanding: 15.8M

Underwriters: Cowen, Piper Jaffray Cos

Co-managers: Canaccord Genuity, Nomura Secs Intl

Company Counsel: Goodwin Procter & Hoar

Manager Counsel: Cooley LLP

Auditor: McGladrey & Pullen LLP

Market Capitalization on 2/27/15: $ 95.58M

Close price on 2/27/15: $ 6.02

Investment Details

Venture Backers:

  • Rho Capital Partners Inc
  • Care Capital LLC
  • Medimmune LLC
  • Pitango Venture Capital Management Israel, Ltd.
  • CDP Capital Private Equity
  • Devon Park Bioventures LP
  • Bio*One Capital Pte Ltd
  • Mitsubishi UFJ Capital Co Ltd
  • Hercules Technology Growth Capital Inc
  • Horizon Technology Finance Management LLC
  • Undisclosed investors

Financing Rounds:

  • 2/1/04 $17M
  • 4/13/04 $3M
  • 8/30/05 $25M
  • 11/17/05 $10M
  • 5/31/06 $64M
  • 8/23/07 $19M
  • 6/10/10 $18M
  • 5/3/11 $584K
  • 7/15/11 $5.6M
  • 9/27/13 n/a
  • 9/27/13 $14M

Source: Data provided by Thomson Reuters.